全文获取类型
收费全文 | 222篇 |
免费 | 30篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 16篇 |
妇产科学 | 3篇 |
基础医学 | 49篇 |
口腔科学 | 10篇 |
临床医学 | 30篇 |
内科学 | 45篇 |
皮肤病学 | 3篇 |
神经病学 | 10篇 |
特种医学 | 27篇 |
外科学 | 11篇 |
综合类 | 29篇 |
预防医学 | 10篇 |
眼科学 | 3篇 |
药学 | 4篇 |
肿瘤学 | 6篇 |
出版年
2022年 | 4篇 |
2021年 | 8篇 |
2019年 | 1篇 |
2018年 | 4篇 |
2017年 | 2篇 |
2016年 | 2篇 |
2015年 | 4篇 |
2014年 | 11篇 |
2013年 | 5篇 |
2012年 | 7篇 |
2011年 | 6篇 |
2010年 | 6篇 |
2009年 | 9篇 |
2008年 | 10篇 |
2007年 | 10篇 |
2006年 | 7篇 |
2005年 | 6篇 |
2004年 | 4篇 |
2003年 | 5篇 |
2002年 | 3篇 |
2001年 | 4篇 |
2000年 | 4篇 |
1999年 | 5篇 |
1998年 | 17篇 |
1997年 | 14篇 |
1996年 | 13篇 |
1995年 | 8篇 |
1994年 | 9篇 |
1993年 | 8篇 |
1992年 | 2篇 |
1991年 | 2篇 |
1990年 | 3篇 |
1989年 | 2篇 |
1988年 | 8篇 |
1987年 | 4篇 |
1986年 | 7篇 |
1985年 | 1篇 |
1984年 | 3篇 |
1983年 | 4篇 |
1982年 | 1篇 |
1981年 | 4篇 |
1979年 | 6篇 |
1978年 | 1篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1975年 | 3篇 |
1974年 | 1篇 |
1972年 | 1篇 |
1970年 | 1篇 |
1967年 | 2篇 |
排序方式: 共有257条查询结果,搜索用时 15 毫秒
71.
This article has no abstract. To view the article, select the "View Print Version (PDF)" link above. 相似文献
72.
Effects of hematopoietin-1 and interleukin 1 activities on early hematopoietic cells of the bone marrow 总被引:3,自引:0,他引:3
Hematopoietin-1 (H-1) was purified from the human cell line 5637 and two amino acid sequences were observed in the preparation. One sequence was identical to that of interleukin 1 alpha (IL 1 alpha) and the other to that of IL 1 beta. The action of recombinant IL 1 alpha and other hematopoietic growth factors was studied using (a) a high proliferative potential colony-forming cell assay that uses primitive hematopoietic precursors from bone marrow, and (b) a spleen colony-forming unit assay. The results indicate that the IL 1 alpha target cell population is different than the target cell populations of IL 3, granulocyte- macrophage colony-stimulating factor; that IL 1 alpha in combination with mononuclear phagocyte colony-stimulating factor provides a proliferative stimulus; and that IL 1 alpha has at least a survival- enhancing and possibly proliferation-inducing effect on primitive hematopoietic stem cells. 相似文献
73.
Nason-Burchenal K; Gandini D; Botto M; Allopenna J; Seale JR; Cross NC; Goldman JM; Dmitrovsky E; Pandolfi PP 《Blood》1996,88(10):3926-3936
74.
Methyl-hydroxylated metabolites of the potent carcinogen, 7,12-
dimethylbenz[a]anthracene (DMBA), namely, 7-hydroxymethyl-12-
methylbenz[a]anthracene (7-OH-DMBA), 7-methyl-12-
hydroxymethylbenz[a]anthracene (12-OH-DMBA) and 7,12-
dihydroxymethylbenz[a]anthracene (7,12-diOH-DMBA), were examined as
substrates for sulfotransferase bioactivation in different human tissue
cytosols. Hepatic cytosols, which were able to catalyze the 3'-
phosphoadenosine 5'-phosphosulfate (PAPS)-dependent DNA binding of 7-OH-
DMBA, 12-OH-DMBA and 7,12-diOH-DMBA, were highly sensitive to inhibition by
dehydroepiandrosterone (DHEA), a specific substrate for human DHEA-steroid
sulfotransferase (IC50 = 5 microM). By comparison,
2,6-dichloro-4-nitrophenol, a potent inhibitor of the thermostable (TS)-
phenol and estrogen sulfotransferases, did not have an appreciable
inhibitory effect. Neither p-nitrophenol, a high affinity substrate for
human TS-phenol and estrogen sulfotransferases, nor dopamine, a specific
substrate for the thermolabile (TL)-phenol sulfotransferase, significantly
inhibited the DNA binding of 12-OH-DMBA catalyzed by hepatic cytosols.
Inter-subject variation (n = 12) of the PAPS- dependent DNA binding of
12-OH- and 7,12-diOH-DMBAs also correlated well with DHEA-sulfotransferase
activity (r = 0.90; P < 0.00001 and r = 0.92; P < 0.00001,
respectively). This sulfation-dependent metabolic activation was not
detected in cytosols from human colon, pancreas, larynx or mammary gland.
Both TS- and TL-phenol sulfotransferases were active in human liver and
colon but only liver contained DHEA- sulfotransferase activity. These
results indicate that the sulfotransferase-mediated activation of the
methyl-hydroxylated DMBAs is predominantly catalyzed by DHEA-steroid
sulfotransferase in human liver and that TS- and TL-phenol
sulfotransferases and estrogen sulfotransferase are not involved in the
catalysis.
相似文献
75.
Sixten Krper Manfred Weiss Daniel Zickler Thomas Wiesmann Kai Zacharowski Victor M. Corman Beate Grüner Lucas Ernst Peter Spieth Philipp M. Lepper Martin Bentz Sebastian Zinn Gregor Paul Johannes Kalbhenn Matthias M. Dollinger Peter Rosenberger Thomas Kirschning Thomas Thiele Thomas Appl Benjamin Mayer Michael Schmidt Christian Drosten Hinnerk Wulf Jan Matthias Kruse Bettina Jungwirth Erhard Seifried Hubert Schrezenmeier the CAPSID Clinical Trial Group 《The Journal of clinical investigation》2021,131(20)
BACKGROUNDCOVID-19 convalescent plasma (CCP) has been considered a treatment option for COVID-19. This trial assessed the efficacy of a neutralizing antibody containing high-dose CCP in hospitalized adults with COVID-19 requiring respiratory support or intensive care treatment.METHODSPatients (n = 105) were randomized 1:1 to either receive standard treatment and 3 units of CCP or standard treatment alone. Control group patients with progress on day 14 could cross over to the CCP group. The primary outcome was a dichotomous composite outcome of survival and no longer fulfilling criteria for severe COVID-19 on day 21.ResultsThe primary outcome occurred in 43.4% of patients in the CCP group and 32.7% in the control group (P = 0.32). The median time to clinical improvement was 26 days in the CCP group and 66 days in the control group (P = 0.27). The median time to discharge from the hospital was 31 days in the CCP group and 51 days in the control group (P = 0.24). In the subgroup that received a higher cumulative amount of neutralizing antibodies, the primary outcome occurred in 56.0% of the patients (vs. 32.1%), with significantly shorter intervals to clinical improvement (20 vs. 66 days, P < 0.05) and to hospital discharge (21 vs. 51 days, P = 0.03) and better survival (day-60 probability of survival 91.6% vs. 68.1%, P = 0.02) in comparison with the control group.ConclusionCCP added to standard treatment was not associated with a significant improvement in the primary and secondary outcomes. A predefined subgroup analysis showed a significant benefit of CCP among patients who received a larger amount of neutralizing antibodies.Trial registrationClinicalTrials.gov .FundingBundesministerium für Gesundheit (German Federal Ministry of Health): ZMVI1-2520COR802. NCT04433910相似文献
76.
77.
78.
Background : A retrospective assessment of contrast enhanced computed tomography (CECT) scan findings in histopathologically proven cases of carcinoma of the gallbladder (GB) was performed to review its role in diagnosis, staging and assessment of surgical resectability. 相似文献
79.
80.